publication date: Dec. 15, 2017
Issue 46 - Dec. 15, 2017
  • “We’re gonna free the data,” Sharpless pledges at NCI Town Hall

    In his first talk to  NCI staff, director Norman “Ned” Sharpless presented himself as an institute insider—highlighting his career-long relationships with NCI and its “legends,” demonstrating his grasp of the institute’s agenda and research portfolio.

  • Five health systems join Strata Oncology network to sequence and match patients to targeted therapy trials

    Five health care systems have joined a precision oncology network that sequences patients’ tumors at no cost and matches patients to clinical trials.

  • As FDA, AHRQ spar over incidence estimates for uterine sarcomas, FDA reiterates recommendation to restrict power morcellation

    About one in 225 to one in 580 women who undergo surgery for fibroids may have hidden uterine cancers, FDA concluded in a recent review of medical studies published over the past four years.

    The updated estimate is generally consistent with one contained in the agency’s 2014 review, FDA officials said in a statement Dec. 14. Three years ago,  the agency estimated that  one in 350 women undergoing such surgery may have a previously undiagnosed sarcoma.

  • Anticipating fundamental change in oncology

    In 2017, The Cancer Letter’s readership grew by over 40 percent and the number of page views has nearly doubled from the 2016 level.

    On an average day in 2017, our website got over 1,700 visits and over 12,500 page views. By way of comparison, in 2016, we gauged 1,200 visits and 6,800 page views. We are losing the right to call ourselves a small publication.

  • In Brief

    • AACR urges House-Senate conference to remove tax bill provisions penalizing future scientists, patients, survivors
    • 2017 AACR-Bayer Innovation and Discovery Grants recipients announced
    • USPSTF recommends against hormone therapy for preventing chronic conditions 
    • Jason Incorvati joins hem/onc department at New Fox Chase East Norriton Campus
  • Drugs and Targets

    • Fate Therapeutics completes technology transfer and starts IND-enabling manufacture of FT500

Copyright (c) 2018 The Cancer Letter Inc.